(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…
U.S. Teaching Hospitals Are Expensive, But Have Lower Death Rates
(Reuters Health)—Academic medical centers, increasingly spurned by insurers for being more expensive than community hospitals, appear to have lower death rates for older adults than other facilities, a U.S. study suggests. Researchers reviewed millions of records for patients aged 65 and older and insured by Medicare, the U.S. health program for the elderly. They found…
Medicaid Cuts Coming in Trump Budget
WASHINGTON (Reuters)—U.S. President Donald Trump’s budget proposal, set to be unveiled on Tuesday, will include cuts to Medicaid and propose changes to other assistance programs for low-income citizens, The Washington Post reported on Sunday. The White House did not immediately respond to a request for comment. A Republican healthcare bill that passed the U.S. House…
Trump Administration Asks for Time to Weigh Obamacare Subsidies
WASHINGTON (Reuters)—The Trump administration and U.S. House of Representatives Republicans on Monday asked a federal court for more time to decide how to proceed on the cost-sharing subsidies paid to health insurers that play a vital role in the Obamacare healthcare law. In a joint filing submitted to the U.S. Court of Appeals for the…
Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis
The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…
Histamine 4 Receptor Promotes Osteoclastogenesis in RA
In a recent study, researchers examined the osteoclastogenic role of the histamine 4 receptor (H4R), measuring the peripheral blood and synovial fluid monocytes in patients with RA. Results showed that multiple cytokines stimulated H4R expression, suggesting the blockage of H4R may be a useful drug target to decrease the joint damage associated with RA…
ACR Leaders & Volunteers Take the Issues to the Decision Makers
On May 11, ACR leaders representing the Board of Directors, Affiliate Society Council, Government Affairs Committee (GAC), Committee on Rheumatologic Care, RheumPAC Committee and Insurance Subcommittee went to Capitol Hill to advocate on behalf of the ACR/ARHP membership and our patients. The group, which represents 27 states and the District of Columbia, conducted meetings in…
ACR Holds Its Ground Amid Rapid-Fire Changes in D.C.
Greetings from your advocacy team in Washington, D.C.! The tectonic plates of the U.S. political landscape continue to shift. The latest: President Trump fired FBI Director James Comey on Tuesday, May 16; since then, Congress and journalists have had very little bandwidth for much else. But healthcare advocates remember just several news cycles ago when…
Optical Workings: Specialists Must Communicate to Treat Eye Disease
In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…
Rheumatologist-Nobel Laureate Dr. Baruch (Barry) Blumberg Deserves Recognition
I read with pleasure the March 2017 Rheuminations (written by Simon M. Helfgott, MD), but wanted to make a small emendation. There is one other rheumatologist–Nobel Laureate besides Philip Hench. Baruch (Barry) Blumberg (1925–2011) was a bona fide rheumatologist who trained in the mid-1950s with the renowned Charles Ragan at Columbia-Presbyterian Medical Center in New…
- « Previous Page
- 1
- …
- 406
- 407
- 408
- 409
- 410
- …
- 796
- Next Page »